
Gossamer Bio, Inc.
97
Recent developments include financing activities, regulatory submissions, and clinical trial updates related to seralutinib and corporate actions such as stockholder approvals.
- Gossamer Bio stockholders approved a share issuance proposal under a securities purchase agreement dated August 20, 2026, supporting capital structure enhancement [N2].
- The company secured up to $250 million in financing to advance seralutinib toward FDA approval, strengthening its financial position [N3].
- Gossamer Bio reported a Q2 2026 loss but topped revenue estimates, reflecting ongoing operational expenditures and revenue generation efforts [N4].
- The company submitted an NDA for seralutinib in September 2026 following FDA feedback and ongoing data analyses [N8].
- Enrollment in the SERANATA Phase 3 study for PH-ILD remains paused pending further evaluation of clinical data and regulatory engagement [S2].
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of seralutinib, an inhaled kinase inhibitor targeting PDGFR α/β, CSF1R, and c-KIT pathways for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company’s strategy centers on advancing seralutinib through regulatory pathways, including a recently submitted NDA, and strengthening its capital structure to support development and potential commercialization. Gossamer Bio collaborates with Chiesi for global development and commercialization efforts outside the United States. The company also pursues development of RT234 under an option agreement with Respira Therapeutics. As of late 2026, Gossamer Bio is navigating clinical trial data analyses, regulatory engagement, and financing activities to support its lead asset’s advancement.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing seralutinib for pulmonary hypertension, including PAH and PH-ILD. The company completed a Phase 3 PROSERA trial with mixed results and submitted an NDA in September 2026 following FDA feedback. It secured up to $250 million financing to advance seralutinib toward FDA approval. As of September 30, 2026, the company reported $51.2 million in cash and equivalents, a net loss of $48.1 million for the quarter, and liquidity ratios indicating constraints. Management has extensive biopharma experience. The company faces regulatory and capital risks amid ongoing clinical and commercial development efforts. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The bull case for Gossamer Bio centers on seralutinib’s potential to address unmet needs in PAH and PH-ILD by targeting underlying pathological remodeling mechanisms. Positive signals in higher risk patient subgroups and orphan drug designations support potential market differentiation. The company’s recent financing and NDA submission demonstrate progress toward regulatory milestones. Collaboration with Chiesi enhances global development and commercialization capabilities. If regulatory approval is obtained, seralutinib could provide a novel therapeutic option in a multi-billion dollar market with significant morbidity and mortality.
The bear case involves the uncertainty of regulatory approval given that the Phase 3 PROSERA trial did not meet its primary endpoint and the FDA’s discretion in evaluating the totality of clinical data. Additional clinical trials or studies may be required, increasing development costs and delaying potential approval. The company faces liquidity constraints with current ratios below 1.0 and significant net losses. Failure to secure additional capital or strategic partnerships could impair development and commercialization efforts. Market competition and challenges in demonstrating clinical benefit over existing therapies also pose risks.
Gossamer Bio’s moat is primarily based on its proprietary inhaled seralutinib molecule targeting multiple kinase pathways implicated in PAH pathology, including PDGFR α/β, CSF1R, and c-KIT. The orphan drug designations granted by regulatory agencies provide exclusivity benefits. The company’s collaboration with Chiesi leverages combined development and commercialization expertise. However, as a clinical-stage biopharmaceutical company, its moat is contingent on successful regulatory approval and market adoption of seralutinib, which remains uncertain given clinical trial outcomes and regulatory review processes.
• Regulatory Approval Uncertainty: The Phase 3 PROSERA trial did not meet its primary endpoint, and the FDA retains substantial discretion in approving seralutinib. Additional clinical trials or data may be required, potentially delaying or preventing approval.
• Capital and Liquidity Constraints: As of September 30, 2026, the company had a current ratio of 0.6 and reported significant net losses. Failure to raise additional capital could limit the ability to continue development and commercialization.
• Clinical Development Risks: Paused enrollment in the SERANATA trial and ongoing data analyses introduce uncertainty in clinical development timelines and outcomes.
• Market and Competitive Risks: PAH treatment is competitive with existing therapies. Demonstrating meaningful clinical benefit and achieving market adoption pose challenges.
Business trends: Focus on advancing seralutinib through regulatory pathways for PAH and PH-ILD, supported by clinical trial data analyses and collaboration with Chiesi.
Execution milestones: NDA submission in September 2026, ongoing FDA engagement, financing secured to support development, and paused SERANATA enrollment pending data review.
Key risks: Regulatory approval uncertainty due to Phase 3 trial results, capital and liquidity constraints, potential need for additional clinical trials, and competitive market dynamics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD).
- The company’s lead product candidate, seralutinib (GB002), is an inhaled small molecule inhibitor targeting PDGFR α/β, CSF1R, and c-KIT pathways, designed to reverse pathological remodeling in PAH.
- Seralutinib has orphan drug designation from FDA, European Commission, and Japan's PMDA for PAH.
- The company completed a Phase 3 PROSERA trial in 390 PAH patients, which showed a placebo-adjusted improvement in 6-minute walk distance (6MWD) at Week 24 of 13.3 meters (p=0.0320), missing the prespecified alpha threshold of 0.025.
- In a higher risk subgroup (REVEAL 2 Lite Risk Score ≥6), seralutinib showed a 20.0m placebo-adjusted improvement in 6MWD with nominal p=0.0207 and positive signals on secondary endpoints.
- Enrollment in the SERANATA Phase 3 study for PH-ILD is paused pending further evaluation of PROSERA data and regulatory engagement.
- The company submitted a New Drug Application (NDA) for seralutinib for PAH treatment in September 2026 following FDA Type B meeting feedback.
- FDA characterized statistical significance and treatment effect in PROSERA as review issues rather than filing issues, but ultimate approval remains uncertain.
- Gossamer Bio has a collaboration agreement with Chiesi for global development and commercialization of seralutinib, with Gossamer leading US efforts for PAH and PH-ILD.
- The company secured up to $250 million in financing in August 2026 to advance seralutinib toward FDA approval.
- As of September 30, 2026, Gossamer Bio had $51.2 million in cash and equivalents, current assets of $60.4 million, current liabilities of $99.9 million, a current ratio of 0.6, and a cash ratio of 0.51, indicating liquidity constraints.
- The company reported a net loss of $48.1 million and basic and diluted EPS of -$7.36 for the quarter ended September 30, 2026.
- Management team includes CEO Faheem Hasnain with extensive biopharma leadership experience, CFO Bryan Giraudo with biotech finance background, and Chief Commercial Officer Bob Smith with over 30 years in pharmaceuticals focused on PAH and rare diseases.
- The company’s near-term strategy focuses on advancing seralutinib regulatory alignment and potential approval, completing data analyses, engaging FDA, and strengthening capital structure.
- The company is also advancing RT234 under an option agreement with Respira Therapeutics, focusing resources on seralutinib development.
- The company’s business risks include uncertainty of FDA approval given PROSERA trial results, potential need for additional clinical trials, capital raising challenges, and possible delays or limitations in commercialization.
- Recent news highlights include stockholder approval of share issuance under a securities purchase agreement in October 2026, and ongoing financing and clinical development updates through November 2026.
Generated 2026-11-11
- S1 | 2026-03-17 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-09 | www.nasdaq.com | TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/tg-therapeutics-tgtx-beats-q3-earnings-and-revenue-estimates
- N2 | 2026-10-28 | www.nasdaq.com | Gossamer Bio Stockholders Approve Share Issuance Proposal Under Securities Purchase Agreement Dated August 20, 2026 | https://www.nasdaq.com/articles/gossamer-bio-stockholders-approve-share-issuance-proposal-under-securities-purchase
- N3 | 2026-08-21 | www.nasdaq.com | Gossamer Secures Up To $250M Financing To Advance Seralutinib Toward FDA Approval | https://www.nasdaq.com/articles/gossamer-secures-250m-financing-advance-seralutinib-toward-fda-approval
- N4 | 2026-08-13 | www.nasdaq.com | Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/gossamer-bio-goss-reports-q2-loss-tops-revenue-estimates
- N5 | 2026-08-13 | www.nasdaq.com | Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/pelthos-therapeutics-inc-pths-reports-q2-loss-lags-revenue-estimates
- N6 | 2026-08-12 | www.nasdaq.com | Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/kura-oncology-kura-reports-q2-loss-beats-revenue-estimates
- N7 | 2026-07-30 | www.nasdaq.com | Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release | https://www.nasdaq.com/articles/prime-medicine-inc-prme-may-report-negative-earnings-know-trend-ahead-q2-release
- N8 | 2026-07-28 | www.nasdaq.com | Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired | https://www.nasdaq.com/articles/top-biotech-gainers-goss-file-seralutinib-nda-sep-omer-gains-azns-loss-fbrx-acquired
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


